Results 41 to 50 of about 11,258 (167)

Differential Impact of Pharmacokinetic and Pharmacodynamic Variability on Response to Combination Therapy

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Interindividual variability (IIV) in drug response complicates both fixed‐dose design and individualized therapy. Understanding how pharmacokinetic (PK) and pharmacodynamic (PD) processes jointly shape this variability is essential, particularly in combination therapy, where multiple interacting pathways influence outcomes. This study employed
Kuteesa R. Bisaso, Ronald Kadada Karyaburo, Jackson K. Mukonzo, Ene I. Ette   +3 more
wiley   +1 more source

Stafib‐2‐CR: an Improved Nanomolar and Selective Inhibitor of the Transcription Factor STAT5b Developed by Conformational Restriction of Stafib‐2

Chemistry – A European Journal, Volume 32, Issue 26, 11 July 2026.
Conformational restriction strategies to increase the activity and selectivity of the STAT5b inhibitor Stafib‐2 are presented. The best conformationally restricted inhibitor Stafib‐2‐CR has threefold higher activity against STAT5b than Stafib‐2. A cell‐permeable prodrug of Stafib‐2‐CR inhibits phosphorylation of STAT5b in cultured human leukemia cells ...
Theresa Münzel, Angela Berg, Christoph Protzel, Sylvie Schäfer, Alexander Jensen‐Feinhals, Thorsten Berg   +5 more
wiley   +1 more source

Apoptosis resistance in chronic myelogenous leukemia [PDF]

Einstein (São Paulo), 2005
The chronic myeloid leukemia (CML) is the three-phasemyeloproliferative disorder, dependent on the expression of theoncoprotein Bcr-Abl, which is the product of the reciprocaltranslocation between chromosomes 9 and 22, resulting in thePhiladelphia ...
Fabíola Attié de Castro, Jacqueline de Fátima Jacysyn, Ana Elisa Bueno-da-Silva, Nelson Hamerschlak, Gustavo Pessini Amarante-Mendes   +4 more
doaj  

BCR‐ABL1 Transcript Variants in Chronic Myeloid Leukemia Patients in Africa: A Systematic Review

Health Science Reports, Volume 9, Issue 7, July 2026.
ABSTRACT Background and Aims The BCR‐ABL1 fusion gene is present in more than 95% of cases of chronic myeloid leukemia (CML), the disease in which it was first described. There are different BCR‐ABL1 fusion transcripts depending on the location of the breakpoints during chromosomal translocation. Identifying these transcripts is important for treatment
Martine Emeline Oloume, Anatole Pieme, Cedric Kekuine Ngalle, Ransir Tapouli, Claude Tayou Tagny   +4 more
wiley   +1 more source

Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules [PDF]

Leukemia, 2000
The Philadelphia (Ph) chromosome, resulting from the t(9;22) translocation, is characteristic of chronic myeloid leukemia (CML). As a result of this translocation, two novel chimeric genes are generated and the bcr/abl and abl/bcr fusion proteins expressed.
Berke, Z., Andersen, M.H., Pedersen, M., Fugger, L., Zeuthen, J.and, Haurum, J.S.   +5 more
openaire   +3 more sources

Cancer Heterogeneity and Cancer Cell Plasticity: Molecular Mechanisms and Precision Therapy

MedComm, Volume 7, Issue 7, July 2026.
Tumor progression is driven by heterogeneity occurring across multiple biological scales. At the molecular level, tumor cells exhibit alterations across distinct omics layers, including genomic mutations, epigenomic reprogramming, transcriptional changes, and proteomic remodeling, collectively shaping tumor cell phenotypes and functional states.
Hanwen Hu, Zhixing Hao, Lili Li, Huiying Liu, Chenghui Yang, Zhen Wang   +5 more
wiley   +1 more source

CGP 57148, a Tyrosine Kinase Inhibitor, Inhibits the Growth of Cells Expressing BCR-ABL, TEL-ABL, and TEL-PDGFR Fusion Proteins [PDF]

Blood, 1997
CGP 57148 is a compound of the 2-phenylaminopyrimidine class that selectively inhibits the tyrosine kinase activity of the ABL and the platelet-derived growth factor receptor (PDGFR) protein tyrosine kinases. We previously showed that CGP 57148 selectively kills p210BCR-ABL–expressing cells. To extend these observations, we evaluated the ability of CGP
M, Carroll, S, Ohno-Jones, S, Tamura, E, Buchdunger, J, Zimmermann, N B, Lydon, D G, Gilliland, B J, Druker   +7 more
openaire   +3 more sources

Drugs that act on both G protein‐coupled receptors (GPCRs) and kinases: potentiation of effects, side effects and general aspects of drug pleiotropy

British Journal of Pharmacology, Volume 183, Issue 13, Page 3471-3483, July 2026.
Abstract Background A drug designed for a specific target often interacts with multiple targets, either unintentionally or as part of its intended mechanism of action. This has been called pharmacological pleiotropy or polypharmacology. There are key endogenous ligands such as ATP, GABA and glutamate that act on various proteins in humans. Furthermore,
Hampus Ljunggren, Aleksandr Sokolov, Flavio Ballante, Robert Fredriksson, Francisco Lagunas‐Rangel, Alexander S. Hauser, Stefan Knapp, Jörgen Jonsson, Helgi B. Schiöth   +8 more
wiley   +1 more source

Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes [PDF]

Leukemia, 2002
Although CD4(+) helper T lymphocytes have been demonstrated to play an important role in antitumor immune response, only a few epitopes of tumor-associated antigens recognized by HLA class II-restricted CD4(+) T lymphocytes have been identified.
M, Makita, T, Azuma, H, Hamaguchi, H, Niiya, K, Kojima, S, Fujita, M, Tanimoto, M, Harada, M, Yasukawa   +8 more
openaire   +2 more sources

A Constellation of Fluorescent Biosensors to Illuminate the Galaxy of Protein Kinases

ChemBioChem, Volume 27, Issue 11, 15 June 2026.
Protein kinases (PKs) are enzymes that catalyze phosphorylation of protein substrates involved in a wide variety of biological signalling pathways. This review describes the different families and mechanisms of action and regulation of protein kinases, together with the different classes of fluorescent biosensors that have been engineered and ...
Timothe Abbura, May C. Morris
wiley   +1 more source